Transcriptional control of metabolic and inflammatory pathways by nuclear receptor SUMOylation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 8, 2011, Pages 909-918

  Treuter, Eckardt ^a   Venteclef, Nicolas ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Acute phase response; GPS2; Inflammation; LRH 1; LXR; Metabolism; N CoR; Nuclear receptor; Post translational modification; PPAR; SMRT; SUMO; Transrepression

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOTIN; CELL NUCLEUS RECEPTOR; CHOLESTEROL 7ALPHA MONOOXYGENASE; COENZYME A; DAXX PROTEIN; HISTONE DEACETYLASE 4; LIVER RECEPTOR HOMOLOG 1; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN UBC9; REACTIVE OXYGEN METABOLITE; RETINOID X RECEPTOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; TRANSCRIPTION FACTOR AP 1;

ANTIINFLAMMATORY ACTIVITY; CELL INTERACTION; CHOLESTEROL TRANSPORT; CONJUGATION; DEVELOPMENT; GENE EXPRESSION; HEAT SHOCK; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LIGAND BINDING; MACROPHAGE; METABOLIC DISORDER; METABOLISM; NONHUMAN; OSMOTIC STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SUMOYLATION; TRANSCRIPTION REGULATION;

HUMANS; INFLAMMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SUMOYLATION; TRANSCRIPTION, GENETIC;

EID: 79958244237     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.12.008     Document Type: Review

References (134)

1. Alarid E.T. Lives and times of nuclear receptors. Mol. Endocrinol. 2006, 20:1972-1981.
2. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 2003, 11:695-707.
3. Hochstrasser M. Origin and function of ubiquitin-like proteins. Nature 2009, 458:422-429.
4. Hay R.T. Role of ubiquitin-like proteins in transcriptional regulation. Ernst Schering Res. Found. Workshop 2006, 173-192.
5. Bossis G., Melchior F. SUMO: regulating the regulator. Cell Div. 2006, 1:13.
6. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
7. Hay R.T. SUMO: a history of modification. Mol. Cell 2005, 18:1-12.
8. Mahajan R., Delphin C., Guan T., Gerace L., Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997, 88:97-107.
9. Palvimo J.J. PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription. Biochem. Soc. Trans. 2007, 35:1405-1408.
10. Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., Rosenfeld M.G., Glass C.K. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 2007, 25:57-70.
11. Xu X., Vatsyayan J., Gao C., Bakkenist C.J., Hu J. HDAC2 promotes eIF4E sumoylation and activates mRNA translation gene specifically. J. Biol. Chem. 2010, 285:18139-18143.
12. Gregoire S., Yang X.J. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol. Cell. Biol. 2005, 25:2273-2287.
13. Treuter E., Gustafsson J.A. Wrestling rules in transrepression: as easy as SUMO-1, -2, -3- Mol. Cell 2007, 25:178-180.
14. Venteclef N., Jakobsson T., Ehrlund A., Damdimopoulos A., Mikkonen L., Ellis E., Nilsson L.M., Parini P., Janne O.A., Gustafsson J.A., Steffensen K.R., Treuter E. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 2010, 24:381-395.
15. Yang S.H., Sharrocks A.D. The SUMO E3 ligase activity of Pc2 is coordinated through a SUMO interaction motif. Mol. Cell. Biol. 2010, 30:2193-2205.
16. Wotton D., Merrill J.C. Pc2 and SUMOylation. Biochem. Soc. Trans. 2007, 35:1401-1404.
17. Pichler A., Gast A., Seeler J.S., Dejean A., Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108:109-120.
18. Chu Y., Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene 2010, Oct 25. [Electronic publication ahead of print].
19. Hay R.T. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 2007, 17:370-376.
20. Yang X.J., Gregoire S. A recurrent phospho-sumoyl switch in transcriptional repression and beyond. Mol. Cell 2006, 23:779-786.
21. Anckar J., Sistonen L. SUMO: getting it on. Biochem. Soc. Trans. 2007, 35:1409-1413.
22. Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J., Nakai A., Sistonen L. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl Acad. Sci. USA 2006, 103:45-50.
23. Tremblay A.M., Wilson B.J., Yang X.J., Giguere V. Phosphorylation-dependent sumoylation regulates estrogen-related receptor-alpha and -gamma transcriptional activity through a synergy control motif. Mol. Endocrinol. 2008, 22:570-584.
24. Golebiowski F., Matic I., Tatham M.H., Cole C., Yin Y., Nakamura A., Cox J., Barton G.J., Mann M., Hay R.T. System-wide changes to SUMO modifications in response to heat shock. Sci. Signal. 2009, 2:ra24.
25. Ulrich H.D. Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol. 2005, 15:525-532.
26. Wu S.Y., Chiang C.M. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J. 2009, 28:1246-1259.
27. Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 2003, 115:565-576.
28. Flick K., Kaiser P. Proteomic revelation: SUMO changes partners when the heat is on. Sci. Signal. 2009, 2:e45.
29. Sarge K.D., Park-Sarge O.K. Sumoylation and human disease pathogenesis. Trends Biochem. Sci. 2009, 34:200-205.
30. Yan D., Davis F.J., Sharrocks A.D., Im H.J. Emerging roles of SUMO modification in arthritis. Gene 2010, 466:1-15.
31. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
32. Glass C.K. Going nuclear in metabolic and cardiovascular disease. J. Clin. Investig. 2006, 116:556-560.
33. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10:365-376.
34. Huang W., Glass C.K. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1542-1549.
35. Glass C.K., Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev. 2006, 6:44-55.
36. Garcia-Bassets I., Kwon Y.S., Telese F., Prefontaine G.G., Hutt K.R., Cheng C.S., Ju B.G., Ohgi K.A., Wang J., Escoubet-Lozach L., Rose D.W., Glass C.K., Fu X.D., Rosenfeld M.G. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007, 128:505-518.
37. Jakobsson T., Venteclef N., Toresson G., Damdimopoulos A.E., Ehrlund A., Lou X., Sanyal S., Steffensen K.R., Gustafsson J.A., Treuter E. GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus. Mol. Cell 2009, 34:510-518.
38. Perissi V., Jepsen K., Glass C.K., Rosenfeld M.G. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 2010, 11:109-123.
39. Bavner A., Sanyal S., Gustafsson J.A., Treuter E. Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends Endocrinol. Metab. 2005, 16:478-488.
40. Lin J., Handschin C., Spiegelman B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005, 1:361-370.
41. Ward R.D., Weigel N.L. Steroid receptor phosphorylation: assigning function to site-specific phosphorylation. Biofactors 2009, 35:528-536.
42. Eroles P., Bosch A., Bermejo B., Lluch A. Mechanisms of resistance to hormonal treatment in breast cancer. Clin. Transl. Oncol. 2010, 12:246-252.
43. Miao J., Xiao Z., Kanamaluru D., Min G., Yau P.M., Veenstra T.D., Ellis E., Strom S., Suino-Powell K., Xu H.E., Kemper J.K. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev. 2009, 23:986-996.
44. Karamouzis M.V., Konstantinopoulos P.A., Badra F.A., Papavassiliou A.G. SUMO and estrogen receptors in breast cancer. Breast Cancer Res. Treat. 2008, 107:195-210.
45. Wu S.C., Zhang Y. Minireview: role of protein methylation and demethylation in nuclear hormone signaling. Mol. Endocrinol. 2009, 23:1323-1334.
46. Popov V.M., Wang C., Shirley L.A., Rosenberg A., Li S., Nevalainen M., Fu M., Pestell R.G. The functional significance of nuclear receptor acetylation. Steroids 2007, 72:221-230.
47. Wu F., Mo Y.Y. Ubiquitin-like protein modifications in prostate and breast cancer. Front. Biosci. 2007, 12:700-711.
48. Talamillo A., Martin D., Hjerpe R., Sanchez J., Barrio R. SUMO and ubiquitin modifications during steroid hormone synthesis and function. Biochem. Soc. Trans. 2010, 38:54-59.
49. Beck I.M., Vanden Berghe W., Vermeulen L., Yamamoto K.R., Haegeman G., De Bosscher K. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr. Rev. 2009, 30:830-882.
50. De Bosscher K., Vanden Berghe W., Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006, 25:6868-6886.
51. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
52. Gottlicher M., Heck S., Doucas V., Wade E., Kullmann M., Cato A.C., Evans R.M., Herrlich P. Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor. Steroids 1996, 61:257-262.
53. Rytinki M.M., Kaikkonen S., Pehkonen P., Jaaskelainen T., Palvimo J.J. PIAS proteins: pleiotropic interactors associated with SUMO. Cell. Mol. Life Sci. 2009, 66:3029-3041.
54. Poukka H., Karvonen U., Janne O.A., Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl Acad. Sci. USA 2000, 97:14145-14150.
55. Hwang E.J., Lee J.M., Jeong J., Park J.H., Yang Y., Lim J.S., Kim J.H., Baek S.H., Kim K.I. SUMOylation of RORalpha potentiates transcriptional activation function. Biochem. Biophys. Res. Commun. 2009, 378:513-517.
56. Ouyang J., Valin A., Gill G. Regulation of transcription factor activity by SUMO modification. Meth. Mol. Biol. 2009, 497:141-152.
57. Gill G. Something about SUMO inhibits transcription. Curr. Opin. Genet. Dev. 2005, 15:536-541.
58. Girdwood D.W., Tatham M.H., Hay R.T. SUMO and transcriptional regulation. Semin. Cell Dev. Biol. 2004, 15:201-210.
59. Chalkiadaki A., Talianidis I. SUMO-dependent compartmentalization in promyelocytic leukemia protein nuclear bodies prevents the access of LRH-1 to chromatin. Mol. Cell. Biol. 2005, 25:5095-5105.
60. Lee M.B., Lebedeva L.A., Suzawa M., Wadekar S.A., Desclozeaux M., Ingraham H.A. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol. Cell. Biol. 2005, 25:1879-1890.
61. Chen W.Y., Lee W.C., Hsu N.C., Huang F., Chung B.C. SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1). J. Biol. Chem. 2004, 279:38730-38735.
62. Park S.W., Hu X., Gupta P., Lin Y.P., Ha S.G., Wei L.N. SUMOylation of Tr2 orphan receptor involves Pml and fine-tunes Oct4 expression in stem cells. Nat. Struct. Mol. Biol. 2007, 14:68-75.
63. Hunter T., Sun H. Crosstalk between the SUMO and ubiquitin pathways. Ernst Schering Found. Symp. Proc. 2008, 1-16.
64. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol. 2005, 19:2671-2684.
65. Li X., Zhang S., Blander G., Tse J.G., Krieger M., Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 2007, 28:91-106.
66. Yang W.H., Heaton J.H., Brevig H., Mukherjee S., Iniguez-Lluhi J.A., Hammer G.D. SUMOylation inhibits SF-1 activity by reducing CDK7-mediated serine 203 phosphorylation. Mol. Cell. Biol. 2009, 29:613-625.
67. Vu E.H., Kraus R.J., Mertz J.E. Phosphorylation-dependent sumoylation of estrogen-related receptor alpha1. Biochemistry 2007, 46:9795-9804.
68. Leuenberger N., Pradervand S., Wahli W. Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. J. Clin. Invest. 2009, 119:3138-3148.
69. Campbell L.A., Faivre E.J., Show M.D., Ingraham J.G., Flinders J., Gross J.D., Ingraham H.A. Decreased recognition of SUMO-sensitive target genes following modification of SF-1 (NR5A1). Mol. Cell. Biol. 2008, 28:7476-7486.
70. Dhillon H., Zigman J.M., Ye C., Lee C.E., McGovern R.A., Tang V., Kenny C.D., Christiansen L.M., White R.D., Edelstein E.A., Coppari R., Balthasar N., Cowley M.A., Chua S., Elmquist J.K., Lowell B.B. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 2006, 49:191-203.
71. Kim K.W., Sohn J.W., Kohno D., Xu Y., Williams K., Elmquist J.K. SF-1 in the ventral medial hypothalamic nucleus: a key regulator of homeostasis. Mol. Cell. Endocrinol. 2010, Nov 24. [Electronic publication ahead of print].
72. Heng J.C., Feng B., Han J., Jiang J., Kraus P., Ng J.H., Orlov Y.L., Huss M., Yang L., Lufkin T., Lim B., Ng H.H. The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell 2010, 6:167-174.
73. Ouyang J., Gill G. SUMO engages multiple corepressors to regulate chromatin structure and transcription. Epigenetics 2009, 4:440-444.
74. Ouyang J., Shi Y., Valin A., Xuan Y., Gill G. Direct binding of CoREST1 to SUMO-2/3 contributes to gene-specific repression by the LSD1/CoREST1/HDAC complex. Mol. Cell 2009, 34:145-154.
75. Stielow B., Sapetschnig A., Kruger I., Kunert N., Brehm A., Boutros M., Suske G. Identification of SUMO-dependent chromatin-associated transcriptional repression components by a genome-wide RNAi screen. Mol. Cell 2008, 29:742-754.
76. Ogawa H., Komatsu T., Hiraoka Y., Morohashi K. Transcriptional suppression by transient recruitment of ARIP4 to sumoylated nuclear receptor Ad4BP/SF-1. Mol. Biol. Cell 2009, 20:4235-4245.
77. Kerscher O. SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep. 2007, 8:550-555.
78. Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T., Ho C.C., Chen Y.C., Lin T.P., Fang H.I., Hung C.C., Suen C.S., Hwang M.J., Chang K.S., Maul G.G., Shih H.M. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 2006, 24:341-354.
79. Saijo K., Winner B., Carson C.T., Collier J.G., Boyer L., Rosenfeld M.G., Gage F.H., Glass C.K. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
80. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
81. De Bosscher K., Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol. Endocrinol. 2009, 23:281-291.
82. Pascual G., Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. TEM 2006, 17:321-327.
83. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
84. Castrillo A., Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 2004, 20:455-480.
85. Zelcer N., Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 2006, 116:607-614.
86. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
87. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
88. Venteclef N., Smith J.C., Goodwin B., Delerive P. Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response. Mol. Cell. Biol. 2006, 26:6799-6807.
89. Blaschke F., Takata Y., Caglayan E., Collins A., Tontonoz P., Hsueh W.A., Tangirala R.K. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 2006, 99:e88-e99.
90. Zhang J., Kalkum M., Chait B.T., Roeder R.G. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol. Cell 2002, 9:611-623.
91. Treuter E., Albrektsen T., Johansson L., Leers J., Gustafsson J.A. A regulatory role for RIP140 in nuclear receptor activation. Mol. Endocrinol. 1998, 12:864-881.
92. Sanyal S., Bavner A., Haroniti A., Nilsson L.M., Lundasen T., Rehnmark S., Witt M.R., Einarsson C., Talianidis I., Gustafsson J.A., Treuter E. Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc. Natl Acad. Sci. USA 2007, 104:15665-15670.
93. Lee J.H., Park S.M., Kim O.S., Lee C.S., Woo J.H., Park S.J., Joe E.H., Jou I. Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol. Cell 2009, 35:806-817.
94. Ghisletti S., Huang W., Jepsen K., Benner C., Hardiman G., Rosenfeld M.G., Glass C.K. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009, 23:681-693.
95. Chao E.Y., Caravella J.A., Watson M.A., Campobasso N., Ghisletti S., Billin A.N., Galardi C., Wang P., Laffitte B.A., Iannone M.A., Goodwin B.J., Nichols J.A., Parks D.J., Stewart E., Wiethe R.W., Williams S.P., Smallwood A., Pearce K.H., Glass C.K., Willson T.M., Zuercher W.J., Collins J.L. Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J. Med. Chem. 2008, 51:5758-5765.
96. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28:551-558.
97. Goodwin B.J., Zuercher W.J., Collins J.L. Recent advances in liver X receptor biology and chemistry. Curr. Top. Med. Chem. 2008, 8:781-791.
98. Zuercher W.J., Buckholz R.G., Campobasso N., Collins J.L., Galardi C.M., Gampe R.T., Hyatt S.M., Merrihew S.L., Moore J.T., Oplinger J.A., Reid P.R., Spearing P.K., Stanley T.B., Stewart E.L., Willson T.M. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J. Med. Chem. 2010, 53:3412-3416.
99. Whitby R.J., Dixon S., Maloney P.R., Delerive P., Goodwin B.J., Parks D.J., Willson T.M. Identification of small molecule agonists of the orphan nuclear receptors liver receptor homolog-1 and steroidogenic factor-1. J. Med. Chem. 2006, 49:6652-6655.
100. Coste A., Dubuquoy L., Barnouin R., Annicotte J.S., Magnier B., Notti M., Corazza N., Antal M.C., Metzger D., Desreumaux P., Brunner T., Auwerx J., Schoonjans K. LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc. Natl Acad. Sci. USA 2007, 104:13098-13103.
101. Navab M., Anantharamaiah G.M., Fogelman A.M. The role of high-density lipoprotein in inflammation. Trends Cardiovasc. Med. 2005, 15:158-161.
102. Chait A., Han C.Y., Oram J.F., Heinecke J.W. Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. J. Lipid Res. 2005, 46:389-403.
103. Trayhurn P., Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 2005, 33:1078-1081.
104. Poitou C., Divoux A., Faty A., Tordjman J., Hugol D., Aissat A., Keophiphath M., Henegar C., Commans S., Clement K. Role of serum amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. J. Clin. Endocrinol. Metab. 2009, 94:1810-1817.
105. Buckingham R.E. Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 2005, 33:167-170.
106. Vavassori P., Mencarelli A., Renga B., Distrutti E., Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 2009, 183:6251-6261.
107. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
108. Gilliver S.C. Sex steroids as inflammatory regulators. J. Steroid Biochem. Mol. Biol. 2010, 120:105-115.
109. Oertelt-Prigione S., Regitz-Zagrosek V. Gender aspects in cardiovascular pharmacology. J. Cardiovasc. Transl. Res. 2009, 2:258-266.
110. Kipp M., Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front. Neuroendocrinol. 2009, 30:188-200.
111. Yang F.M., Pan C.T., Tsai H.M., Chiu T.W., Wu M.L., Hu M.C. Liver receptor homolog-1 localization in the nuclear body is regulated by sumoylation and cAMP signaling in rat granulosa cells. FEBS J. 2009, 276:425-436.
112. Komatsu T., Mizusaki H., Mukai T., Ogawa H., Baba D., Shirakawa M., Hatakeyama S., Nakayama K.I., Yamamoto H., Kikuchi A., Morohashi K. Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic transcription between Ad4BP/SF-1 and Sox9. Mol. Endocrinol. 2004, 18:2451-2462.
113. Burrage P.S., Schmucker A.C., Ren Y., Sporn M.B., Brinckerhoff C.E. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. Arthritis Res. Ther. 2008, 10:R139.
114. Choi S.J., Chung S.S., Rho E.J., Lee H.W., Lee M.H., Choi H.S., Seol J.H., Baek S.H., Bang O.S., Chung C.H. Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1. J. Biol. Chem. 2006, 281:30669-30677.
115. Pourcet B., Pineda-Torra I., Derudas B., Staels B., Glineur C. SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. J. Biol. Chem. 2010, 285:5983-5992.
116. Ohshima T., Koga H., Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J. Biol. Chem. 2004, 279:29551-29557.
117. Jennewein C., Kuhn A.M., Schmidt M.V., Meilladec-Jullig V., von Knethen A., Gonzalez F.J., Brune B. Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines. J. Immunol. 2008, 181:5646-5652.
118. Lim S., Ahn B.Y., Chung S.S., Park H.S., Cho B.J., Kim M., Choi S.H., Lee I.K., Lee S.W., Choi S.J., Chung C.H., Cho Y.M., Lee H.K., Park K.S. Effect of a peroxisome proliferator-activated receptor gamma sumoylation mutant on neointimal formation after balloon injury in rats. Atherosclerosis 2009, 206:411-417.
119. Hu G., Xu C., Staudinger J.L. Pregnane X receptor is SUMOylated to repress the inflammatory response. J. Pharmacol. Exp. Ther. 2010, 335:342-350.
120. Kotaja N., Karvonen U., Janne O.A., Palvimo J.J. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 2002, 22:5222-5234.
121. Callewaert L., Verrijdt G., Haelens A., Claessens F. Differential effect of small ubiquitin-like modifier (SUMO)-ylation of the androgen receptor in the control of cooperativity on selective versus canonical response elements. Mol. Endocrinol. 2004, 18:1438-1449.
122. Mukherjee S., Thomas M., Dadgar N., Lieberman A.P., Iniguez-Lluhi J.A. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J. Biol. Chem. 2009, 284:21296-21306.
123. Holmstrom S., Van Antwerp M.E., Iniguez-Lluhi J.A. Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy. Proc. Natl Acad. Sci. USA 2003, 100:15758-15763.
124. Holmstrom S.R., Chupreta S., So A.Y., Iniguez-Lluhi J.A. SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX. Mol. Endocrinol. 2008, 22:2061-2075.
125. Daniel A.R., Faivre E.J., Lange C.A. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol. Endocrinol. 2007, 21:2890-2906.
126. Kotaja N., Karvonen U., Janne O.A., Palvimo J.J. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J. Biol. Chem. 2002, 277:30283-30288.
127. Rytinki M.M., Palvimo J.J. SUMOylation attenuates the function of PGC-1alpha. J. Biol. Chem. 2009, 284:26184-26193.
128. Rytinki M.M., Palvimo J.J. SUMOylation modulates the transcription repressor function of RIP140. J. Biol. Chem. 2008, 283:11586-11595.
129. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., Garcia-Wilson E., Perkins N.D., Hay R.T. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 2003, 11:1043-1054.
130. Tiefenbach J., Novac N., Ducasse M., Eck M., Melchior F., Heinzel T. SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription. Mol. Biol. Cell 2006, 17:1643-1651.
131. Cheng J., Wang D., Wang Z., Yeh E.T. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol. Cell. Biol. 2004, 24:6021-6028.
132. Rosendorff A., Sakakibara S., Lu S., Kieff E., Xuan Y., DiBacco A., Shi Y., Gill G. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc. Natl Acad. Sci. USA 2006, 103:5308-5313.
133. Domanskyi A., Virtanen K.T., Palvimo J.J., Janne O.A. Biochemical characterization of androgen receptor-interacting protein 4. Biochem. J. 2006, 393:789-795.
134. Oishi Y., Manabe I., Tobe K., Ohsugi M., Kubota T., Fujiu K., Maemura K., Kubota N., Kadowaki T., Nagai R. SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nat. Med. 2008, 14:656-666.